Legal & General Group Plc acquired a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,839 shares of the company's stock, valued at approximately $1,445,000. Legal & General Group Plc owned about 0.06% of Establishment Labs as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ESTA. KBC Group NV bought a new stake in Establishment Labs in the 1st quarter worth approximately $28,000. Quarry LP bought a new position in shares of Establishment Labs during the 3rd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Establishment Labs in the 2nd quarter worth $43,000. Kestra Advisory Services LLC purchased a new position in shares of Establishment Labs in the 4th quarter worth $47,000. Finally, Osaic Holdings Inc. grew its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after acquiring an additional 1,800 shares during the period. Institutional investors own 72.91% of the company's stock.
Establishment Labs Stock Performance
NASDAQ:ESTA opened at $74.29 on Monday. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The stock has a 50-day simple moving average of $83.45 and a two-hundred day simple moving average of $74.89. The firm has a market capitalization of $2.21 billion, a PE ratio of -56.71 and a beta of 1.05. Establishment Labs Holdings Inc. has a 52-week low of $36.53 and a 52-week high of $97.59.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The firm's quarterly revenue was up 31.7% compared to the same quarter last year. During the same period last year, the business earned ($0.57) EPS. Analysts forecast that Establishment Labs Holdings Inc. will post -1.15 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the company. TD Cowen upped their price objective on Establishment Labs from $95.00 to $117.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. raised their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research note on Thursday, August 6th. Mizuho upped their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Finally, Needham & Company LLC increased their price objective on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.25.
Read Our Latest Stock Analysis on Establishment Labs
About Establishment Labs
(
Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
